Presenter: Darin Ingels, ND, FAAEM, FMAPS
Original Date: April 14, 2024

Lyme disease, streptococcus and multiple other microbes are known triggers for autoimmune reactions that can cause gastrointestinal, neurological and connective tissue disorders. Few therapies exist to modulate the immune response and downregulate overexpression toward autoimmunity. Low dose immunotherapy (LDI) is a novel new approach to accomplish that goal. The goals of this lecture are to educate practitioners about the immunological mechanisms behind low dose immunotherapy and how to implement it into clinical practice. LDI is a nosode therapy that evolved from low dose allergy therapy (LDA), developed by Dr. Len McKewen more than 50 years ago. Dr. Ty Vincent developed LDI almost 10 years ago after recognizing that the immune mechanisms involved with allergies was not dissimilar to how the immune system reacted to various microbes. Research shows that microbes, including Lyme, can upregulate Th2 pathways and produce antibodies that cross-react with several proteins on our cell surfaces causing inflammation and symptoms. LDI utilizes diluted inactivated organisms mixed with beta glucuronidase to help modulate Treg cells and downregulate Th2 activity. Patient symptoms often improve after using LDI. Dr. Ingels will discuss the process of antigen selection, dosing schedules, side effects and patient management. He will also present case studies to demonstrate the clinical uses of LDI in practice.

NUNM is accredited by the North American Naturopathic Continuing Education Council (NANCEAC). This activity qualifies for 1.5 General CEUs.